Evotec and Bayer announce new kidney disease study

Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney disease, stemming from their previous collaborative research in this area. The phase 2a ASSESS study will evaluate the efficacy and safety of BAY 3401016, a monoclonal antibody targeting the protein Semaphorin-3A. BAY 3401016 is currently being developed as a potential […] The post Evotec and Bayer announce new kidney disease study appeared first on Pharmafile.

Continue reading →